HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Rapid Responses: Submit a response Alert me when this article is cited Alert me when Rapid Responses are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shrank, W. H. Articles by Asch, S. M. Search for Related Content PubMed PubMed Citation Articles by Shrank, W. H. Articles by Asch, S. M.

A Bitter Pill: Formulary Variability and the Challenge to Prescribing Physicians

Division of General Internal Medicine, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073 (WHS, PG, SMA)
Division of General Internal Medicine and Health Services Research, University of California, Los Angeles (SLE, PG, SMA)

Correspondence: Address correspondence to William Shrank, MD, VA Greater Los Angeles Health Care System, Division of General Internal Medicine (111G), 11301 Wilshire Blvd, Los Angeles, CA 90073 (e-mail: william.shrank{at}med.va.gov)

Background: Multitiered, incentive-based formularies have been increasingly used as a mechanism to control prescription drug expenditures. Prescribing physicians who manage patients from multiple insurers must be familiar with the variability in their patients’ formulary incentives to help patients choose therapy wisely. However, the degree of formulary variability among and within health plans over time is unclear.

Methods: In 6 major health plans in California, we evaluated formulary incentive variability in 4 of the 5 drug classes with the highest expenditures in California: proton pump inhibitors, hydroxymethylglutaryl coenzyme A reductase inhibitors ("statins"), calcium channel blockers, and angiotensin-converting enzyme inhibitors. We categorized 20 branded members of these classes into either "preferred" or nonpreferred/uncovered categories. We calculated the consistency that brands were preferred across health plans and the frequency of changes in formulary status for each drug within plans between 2000 and 2002.

Results: None of the branded drugs evaluated were preferred on all formularies in 2002, and 10% were not available on any of the formularies. Formulary status varied greatly across plans, and more than 60% of drugs were preferred on 2 to 4 of the 6 formularies studied. Formulary status within health plans varied between 2000 and 2002 in more than half of the plans in the drug classes evaluated.

Conclusions: In the drug classes evaluated, over a 2-year period, considerable variability was seen among and within formularies over time. This variability poses a challenge to physicians who wish to reduce patients’ expenditures by prescribing the least expensive among similarly effective drugs within a drug class. This variability is especially relevant because recent legislation increases the likelihood that more Medicare beneficiaries will receive their medications from private health plans.

This article has been cited by other articles:

				C.-W. Tseng, C. M. Mangione, R. H. Brook, E. Keeler, and R. A. Dudley Identifying Widely Covered Drugs and Drug Coverage Variation Among Medicare Part D Formularies JAMA, June 20, 2007; 297(23): 2596 - 2602. [Abstract] [Full Text] [PDF]